R&D channel feed – Endpoints News

R&D channel feed

Scottish biotech debuts with ‘Trojan horse’ platform for cancer

5 months ago

Eisai terminates Phase 3 trial of Dravet drug, citing recruitment challenges

5 months ago

Eyenovia halts Phase 3 myopia trial, to consider selling assets

5 months ago

Boston Pharmaceuticals hits Phase 2 goals as it tries to keep up with MASH competitors

5 months ago

Adaptimmune to 'redefine' itself as a sarcoma biotech, cuts a third of staffers

5 months ago

New Zealand clears first clinical trial of epigenetic editing for hepatitis B

6 months ago

GSK makes case for Blenrep's return with new blood cancer survival data

6 months ago

Danish biotech Gubra touts early weight loss data in hot amylin field

6 months ago

Adaptimmune's second T cell receptor cell therapy for rare sarcomas passes pivotal test

6 months ago

After stock slides, Amgen addresses bone density talk on obesity drug

6 months ago

Syros' shares plummet as blood cancer drug fails again

6 months ago

Syndax's menin inhibitor succeeds in pivotal trial, but investors aren't impressed

6 months ago

Merck, AstraZeneca tout Phase 3 win for cancer-turned-rare disease drug

6 months ago

Merck KGaA plans China submission after late-stage win for tumor drug

6 months ago

Updated: AstraZeneca, Daiichi Sankyo replace lung cancer filing for Enhertu successor

6 months ago

AstraZeneca budgets another $2B to boost manufacturing and R&D in US

6 months ago

Sanofi, OpenAI, Formation Bio debut patient recruiting tool, will use in Phase 3 multiple sclerosis studies

6 months ago

Novartis pays $150M upfront to Schrödinger in new drug deal, ramps up software use

6 months ago

Neurogene's stock falls in post-market trading after early data in Rett syndrome

6 months ago

FDA lifts hold on Novavax vaccines after adverse event reclassified as ALS

6 months ago

Yorvipath’s approval showcases biopharma’s interest in rare endocrine disorder

6 months ago

Assertio denies activist investor's claims of fraud in open letter

6 months ago

Crown jewel from AbbVie's Cerevel buyout fails two Phase 2 schizophrenia tests, Bristol Myers' stock soars

6 months ago

Amgen and AstraZeneca share positive results in chronic rhinosinusitis

6 months ago

First page Previous page 16 17 181920 21 22 Next page Last page